Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Who knows where we are going ?

<< Previous

Bullboard Posts

Next >>

Post by Ingiboyon Mar 03, 2023 12:20am

282 Views

Post# 35316721

Who knows where we are going ?

JC I can't agree with you more. This AGM was an unmitigated disaster. I like you and many others
were led to believe the submission of the Dermal Injector for FDA Approval was imminent. FDA Approval for a device like this has to be tested on a commercial grade device from actual production. The device they have at the moment is not production. Who knows how far away that will be.
We can now forget about the dermal injector as a revenue stream in 2023.

It is now all about this Shiseido Arbitration. Did anyone get anything of value from this AGM relating to this Arbitration ?

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec